Repeated peptide receptor radiotherapy in multiple recurrences of a metastasized neuroendocrine tumor

Nuklearmedizin 2017; 56(03): N19-N21
DOI: 10.3413/Nukmed-0863-16-11

Case report

Schattauer GmbH

Authors

Claudia Brogsitter

¹Nuclear Medicine Department, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
Klaus Zöphel

¹Nuclear Medicine Department, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
Gunnar Folprecht

²Medical Department I, University Cancer Center, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
Grame Eisenhofer

³Medical Department III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany
Jörg Kotzerke

¹Nuclear Medicine Department, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

References
1 Bodei L, Mueller-Brand J, Baum RP. et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2013; 40: 800-816.
2 Kong G, Callahan J, Hofman MS. et al. High clinical and morphologic response using ⁹⁰Y-DOTA-octreotate sequenced with ¹⁷⁷Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2017; 44 (03) 476-489.
3 Pavel M, Baudin E, Couvelard A. et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012; 95: 157-176.
4 Rolleman EJ, Krenning EP, Bernard BF. et al. Longterm toxicity of [(177)Lu-DOTA (0),Tyr (3)]octreotate in rats. Eur J Nucl Med Mol Imaging 2007; 34: 219-227.
5 Sadowski SM, Neychev V, Millo C. et al. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. J Clin Oncol 2016; 34: 588-596.